Why did Agilent Technologies (A) stock move recently?

On 7/23/2026, Agilent Technologies moved +4.7% — Agilent Technologies shares rose with broader market or sector sentiment in life sciences amid steady demand outlook; no specific company catalyst or filing was reported for the July 23 move. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Agilent Technologies (A) overvalued or fairly valued?

MarketChacha shows Agilent Technologies's valuation in context — a trailing P/E of about 36.8, a forward P/E of about 25.8, a price-to-book of about 6.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Agilent Technologies's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.33×) from reported figures — education, not a rating.

What is Agilent Technologies's revenue?

Agilent Technologies reported revenue of $6.9B for FY2025, with net profit of $1.3B, per official filings.

What is the share price of Agilent Technologies (A)?

Agilent Technologies last traded at $174.18 (+2.5% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Agilent Technologies

A · NYSE · Healthcare · United States

Snapshot

TickerA

ExchangeNYSE

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees18,200

HeadquartersSanta Clara, United States

Websitewww.agilent.com

Filings tracked19

About Agilent Technologies

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Who owns it

Insiders0.2%
Institutions95.4%
Public & other4.4%

1,635 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.9.08%
Vanguard Capital Management LLC6.54%
Vanguard Portfolio Management LLC5.12%
State Street Corporation4.56%
Massachusetts Financial Services Co.3.55%
T. Rowe Price Investment Management, Inc.2.75%
Geode Capital Management, LLC2.69%
Wellington Management Group, LLP2.64%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.33×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend18.1% → 18.8%

Margin has held broadly steady over the period — stable profitability.

Return on equity19.3%

Latest ROE of 19.3% — capital is generating a healthy return.

Growth qualityrev 1% · PAT 3%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.9B · EPS 1.50

Est. earnings growth +10.3%

Next fiscal year

Rev $8.0B · EPS 6.75

Est. earnings growth +8.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$6.9B

Net margin

18.8%

ROE

19.3%

Revenue CAGR (2y)

+0.8%

Profit CAGR (2y)

+2.5%

EPS (FY2025)

4.57

Net profit (FY2025)

$1.3B

Ask MarketChacha about A

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Jul 23, 2026
Agilent Technologies shares rose with broader market or sector sentiment in life sciences amid steady demand outlook; no specific company catalyst or filing was reported for the July 23 move.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$6.9B	$1.3B	4.57	18.8%	19.3%
FY2024	$6.5B	$1.3B	4.43	19.8%	21.9%
FY2023	$6.8B	$1.2B	4.19	18.1%	21.2%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q3	$1.9B	$362.0M	1.28	19.3%
2026Q2	$1.8B	$339.0M	1.20	18.5%
2026Q1	$1.8B	$305.0M	1.07	17.0%
2025Q3	$1.7B	$336.0M	1.18	19.3%
2025Q2	$1.7B	$215.0M	0.75	12.9%
2025Q1	$1.7B	$318.0M	1.11	18.9%
2024Q3	$1.6B	$282.0M	0.97	17.9%
2024Q2	$1.6B	$308.0M	1.05	19.6%
2024Q1	$1.7B	$348.0M	1.18	21.0%
2023Q3	$1.7B	$111.0M	0.38	6.6%
2023Q2	$1.7B	$302.0M	1.02	17.6%
2023Q1	$1.8B	$352.0M	1.19	20.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC9/8/2026material
10-Q filing
SEC9/1/2026
8-K — Results of operations, Exhibits
SEC8/26/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC6/25/2026material
10-Q filing
SEC6/1/2026
8-K — Results of operations, Executive/director change, Exhibits
SEC5/27/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC5/4/2026material
8-K/A — Executive/director change, Exhibits
SEC4/6/2026
8-K — Change in control, Exhibits
SEC4/3/2026material
8-K — Bylaw/charter change, Shareholder vote results, Exhibits
SEC3/20/2026material
8-K — Executive/director change, Exhibits
SEC3/6/2026material
10-Q filing
SEC3/3/2026
8-K — Results of operations, Exhibits
SEC2/25/2026material

2025

10-K filing
SEC12/22/2025
8-K — Results of operations, Exhibits
SEC11/24/2025material
8-K — Executive/director change
SEC10/27/2025material
10-Q filing
SEC8/29/2025
8-K — Results of operations, Exhibits
SEC8/27/2025material
8-K/A — Executive/director change
SEC8/8/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.